Castle Biosciences (CSTL) Receivables - Net (2018 - 2026)

Castle Biosciences has disclosed Receivables - Net across 9 years of filings, most recently posting $42.3 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $42.3 million, down 25.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.3 million (down 25.0% YoY), and the FY2025 annual result was $43.4 million, down 15.3% from the prior year.
• Receivables - Net came in at $42.3 million for Q1 2026 at Castle Biosciences, down from $43.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $56.4 million in Q1 2025 to a low of $19.9 million in Q1 2022.
• The 5-year median for Receivables - Net is $42.3 million (2026), against an average of $38.7 million.
• Across the five-year window, Receivables - Net jumped 63.15% in 2023 and retreated 25.0% in 2026, its largest moves.
• Castle Biosciences' Receivables - Net stood at $23.5 million in 2022, then jumped by 63.15% to $38.3 million in 2023, then jumped by 33.72% to $51.2 million in 2024, then slipped by 15.3% to $43.4 million in 2025, then slipped by 2.58% to $42.3 million in 2026.
• The last three Receivables - Net figures came in at $42.3 million (Q1 2026), $43.4 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.